The Evolving Role Of Biomarkers In Oncology Clinical Trial Design


In the second installment of the Clinical Leader series, Precision’s David Parker discusses the incorporation of biomarkers in oncology clinical trials to achieve both clinical and commercial success in today’s value-focused reimbursement environment. The Clinical Leader series explores the shift from volume- to value-based healthcare reimbursement in the United States. 

To read the full article, please click here.

For the first installment in this three-part series, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.